Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice

Geeta Sandhu; Josephine Adattini; Evangeline Armstrong Gordon; Niamh O'Neill; Corrinne Bagnis; Alan V. Boddy; Pinkie Chambers; Alex Flynn; Brett Hamilton; Karim Ibrahim; David W. Johnson; Christos Karapetis; Aisling Kelly; Kimberley-Ann Kerr; Ganessan Kichenadasse; David S. Kliman; Craig Kurkard; Winston Liauw; Catherine Lucas; Andrew J. Mallett; Jolant Malyszko; Georgia McCaughan; Michael Michael; Sanja Mirkov; Emma Morris; Carol A. Pollock; Darren M. Roberts; David J. Routledge; Carla Scuderi; Julia Shingleton; Jake Shortt; Jim Siderov; Ben Sprangers; Brian N. Stein; Amanda Tey; Kate Webber; Jenny Wichart; Rachel Wong; Robyn L. Ward; ADDIKD Working Group

doi:10.1016/j.eclinm.2025.103161

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice

Geeta Sandhu, Josephine Adattini, Evangeline Armstrong Gordon, Niamh O'Neill, Corrinne Bagnis, Alan V. Boddy, Pinkie Chambers, Alex Flynn, Brett Hamilton, Karim Ibrahim, David W. Johnson, Christos Karapetis, Aisling Kelly, Kimberley-Ann Kerr, Ganessan Kichenadasse, David S. Kliman, Craig Kurkard, Winston Liauw, Catherine Lucas, Andrew J. MallettJolant Malyszko, Georgia McCaughan, Michael Michael, Sanja Mirkov, Emma Morris, Carol A. Pollock, Darren M. Roberts, David J. Routledge, Carla Scuderi, Julia Shingleton, Jake Shortt, Jim Siderov, Ben Sprangers, Brian N. Stein, Amanda Tey, Kate Webber, Jenny Wichart, Rachel Wong, Robyn L. Ward, ADDIKD Working Group

College of Medicine and Public Health

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

60 Downloads (Pure)

Abstract

Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, ‘change championing’ by clinicians locally and encouraging its integration into existing reference sources, clinical trial protocols and electronic prescribing systems.

Original language	English
Article number	103161
Number of pages	11
Journal	EClinicalMedicine
Volume	82
DOIs	https://doi.org/10.1016/j.eclinm.2025.103161
Publication status	Published - Apr 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Chemotherapy
Drug dosing
Haematology
Kidney dysfunction
Oncology
Pharmacokinetics
Renal

Access to Document

10.1016/j.eclinm.2025.103161Licence: CC BY

Published versionFinal published version, 1.19 MBLicence: CC BY

Cite this

Sandhu, G., Adattini, J., Armstrong Gordon, E., O'Neill, N., Bagnis, C., Boddy, A. V., Chambers, P., Flynn, A., Hamilton, B., Ibrahim, K., Johnson, D. W., Karapetis, C., Kelly, A., Kerr, K.-A., Kichenadasse, G., Kliman, D. S., Kurkard, C., Liauw, W., Lucas, C., ... ADDIKD Working Group (2025). Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice. EClinicalMedicine, 82, Article 103161. https://doi.org/10.1016/j.eclinm.2025.103161

@article{9ca12e036c434c18aa4f947b2edbd334,

title = "Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice",

abstract = "Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, {\textquoteleft}change championing{\textquoteright} by clinicians locally and encouraging its integration into existing reference sources, clinical trial protocols and electronic prescribing systems. ",

keywords = "Chemotherapy, Drug dosing, Haematology, Kidney dysfunction, Oncology, Pharmacokinetics, Renal",

author = "Geeta Sandhu and Josephine Adattini and {Armstrong Gordon}, Evangeline and Niamh O'Neill and Corrinne Bagnis and Boddy, {Alan V.} and Pinkie Chambers and Alex Flynn and Brett Hamilton and Karim Ibrahim and Johnson, {David W.} and Christos Karapetis and Aisling Kelly and Kimberley-Ann Kerr and Ganessan Kichenadasse and Kliman, {David S.} and Craig Kurkard and Winston Liauw and Catherine Lucas and Mallett, {Andrew J.} and Jolant Malyszko and Georgia McCaughan and Michael Michael and Sanja Mirkov and Emma Morris and Pollock, {Carol A.} and Roberts, {Darren M.} and Routledge, {David J.} and Carla Scuderi and Julia Shingleton and Jake Shortt and Jim Siderov and Ben Sprangers and Stein, {Brian N.} and Amanda Tey and Kate Webber and Jenny Wichart and Rachel Wong and Ward, {Robyn L.} and {ADDIKD Working Group}",

year = "2025",

month = apr,

doi = "10.1016/j.eclinm.2025.103161",

language = "English",

volume = "82",

journal = "EClinicalMedicine",

issn = "2589-5370",

publisher = "Elsevier",

}

Sandhu, G, Adattini, J, Armstrong Gordon, E, O'Neill, N, Bagnis, C, Boddy, AV, Chambers, P, Flynn, A, Hamilton, B, Ibrahim, K, Johnson, DW, Karapetis, C, Kelly, A, Kerr, K-A, Kichenadasse, G, Kliman, DS, Kurkard, C, Liauw, W, Lucas, C, Mallett, AJ, Malyszko, J, McCaughan, G, Michael, M, Mirkov, S, Morris, E, Pollock, CA, Roberts, DM, Routledge, DJ, Scuderi, C, Shingleton, J, Shortt, J, Siderov, J, Sprangers, B, Stein, BN, Tey, A, Webber, K, Wichart, J, Wong, R, Ward, RL & ADDIKD Working Group 2025, 'Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice', EClinicalMedicine, vol. 82, 103161. https://doi.org/10.1016/j.eclinm.2025.103161

TY - JOUR

T1 - Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice

AU - Sandhu, Geeta

AU - Adattini, Josephine

AU - Armstrong Gordon, Evangeline

AU - O'Neill, Niamh

AU - Bagnis, Corrinne

AU - Boddy, Alan V.

AU - Chambers, Pinkie

AU - Flynn, Alex

AU - Hamilton, Brett

AU - Ibrahim, Karim

AU - Johnson, David W.

AU - Karapetis, Christos

AU - Kelly, Aisling

AU - Kerr, Kimberley-Ann

AU - Kichenadasse, Ganessan

AU - Kliman, David S.

AU - Kurkard, Craig

AU - Liauw, Winston

AU - Lucas, Catherine

AU - Mallett, Andrew J.

AU - Malyszko, Jolant

AU - McCaughan, Georgia

AU - Michael, Michael

AU - Mirkov, Sanja

AU - Morris, Emma

AU - Pollock, Carol A.

AU - Roberts, Darren M.

AU - Routledge, David J.

AU - Scuderi, Carla

AU - Shingleton, Julia

AU - Shortt, Jake

AU - Siderov, Jim

AU - Sprangers, Ben

AU - Stein, Brian N.

AU - Tey, Amanda

AU - Webber, Kate

AU - Wichart, Jenny

AU - Wong, Rachel

AU - Ward, Robyn L.

AU - ADDIKD Working Group

PY - 2025/4

Y1 - 2025/4

N2 - Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, ‘change championing’ by clinicians locally and encouraging its integration into existing reference sources, clinical trial protocols and electronic prescribing systems.

AB - Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, ‘change championing’ by clinicians locally and encouraging its integration into existing reference sources, clinical trial protocols and electronic prescribing systems.

KW - Chemotherapy

KW - Drug dosing

KW - Haematology

KW - Kidney dysfunction

KW - Oncology

KW - Pharmacokinetics

KW - Renal

UR - http://www.scopus.com/inward/record.url?scp=105000979548&partnerID=8YFLogxK

U2 - 10.1016/j.eclinm.2025.103161

DO - 10.1016/j.eclinm.2025.103161

M3 - Review article

AN - SCOPUS:105000979548

SN - 2589-5370

VL - 82

JO - EClinicalMedicine

JF - EClinicalMedicine

M1 - 103161

ER -

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this